ESSEX BIO-TECH's subsidiary has been approved for the commercialization of multi-dose sodium dequalinium eye drops in China
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, ESSEX BIO-TECH announced that its indirectly wholly-owned subsidiary, Zhuhai ESSEX Bio-Pharmaceutical Co., Ltd., has obtained approval from the National Medical Products Administration to register and commercialize multi-dose Diquafosol Sodium Eye Drops in mainland China (approved product). The approved product is a multi-dose eye drop containing 3% (5ml: 150mg) Diquafosol Sodium, suitable for the treatment of dry eye syndrome (such as conjunctival epithelial damage and tear abnormalities)
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments